Decreasing incidence of inflammatory bowel disease in Eastern Canada: a population database study

BMC Gastroenterology

Adrian R Levy³  Hala Tamim¹  Desmond Leddin² 

[1] Kinesiology and Health Sciences, York University, Toronto, Canada;Department of Medicine, Dalhousie University, 912 Victoria, Victoria General Hsopital, Halifax, NS B3H 2Y9, Canada;Epidemiology and Community Health, Dalhousie University, Halifax, Canada

关键词: Epidemiology;    Ulcerative colitis;    Inflammatory bowel disease;    Crohn’s;   

Others  :  1121853
DOI  :  10.1186/1471-230X-14-140

 received in 2014-03-02, accepted in 2014-08-05,  发布年份 2014

【 摘 要 】

Background

Nova Scotia has one of the highest incidences of inflammatory bowel disease (IBD) in the world. We wished to determine trends of IBD over time.

Methods

All Provincial residents have government provided health insurance and all interactions with the hospital, and physician billing systems, are captured on an administrative database. We used a validated measure to define incident cases of Crohn’s (CD), ulcerative colitis (UC) and undifferentiated IBD (IBDU). Incidence rates of these diseases for the years 1996–2009 were calculated.

Results

Over the study period, 7,153 new cases of IBD were observed of which 3,046 cases were categorized as CD (42.6%), 2,960 as UC (41.4%) and 1,147 as IBDU (16.0%). Annual age standardized incidence rates were very high but have declined for CD from 27.4 to 17.7/100,000 population and for UC from 21.4 to 16.7/100,000. The decline was seen in all age groups and both genders. The decrease was not explained by a small increase in IBDU.

Conclusion

The incidence of CD and UC are decreasing in Nova Scotia. If replicated elsewhere this indicates a reversal after a long period of increasing occurrence of IBD. This has implications for both epidemiology and health planning.

【 授权许可】

   
2014 Leddin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH: Indeterminate colitis: a review of the concept-what's in a name? Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2008, 14(6):850-7.
• [2]Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, Dotan I, Goh KL, Hibi T, Kozarek RA, Quigley EM, Reinisch W, Sands BE, Sollano JD, Steinhart AH, Steinwurz F, Vatn MH, Yamamoto-Furusho JK: IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010–Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis 2011, 17(2):639-44.
• [3]Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142(1):46-54.
• [4]Lowe A-M, Roy PO, B-Poulin M, Michel P, Bitton A, St-Onge L, Brassard P: Epidemiology of Crohn’s disease in Québec. Canada Inflamm Bowel Dis 2009, 15(3):429-435.
• [5]Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A: Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999, 149(10):916-24.
• [6]Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P: Small-area variations and sociodemographic correlates for the incidence of Crohn’s disease and ulcerative colitis. Am J Epidemiol 2001, 154(4):328-35.
• [7]Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF: The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006, 101(7):1559-68.
• [8]Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006, 12:S3-9.
• [9]Loftus EV Jr: The burden of inflammatory bowel disease in the United States: a moving target? Clin Gastroenterol Hepatol 2007, 5(12):1383-84.
• [10]Government of Nova Scotia: Economics and Statistics. Archived daily statistics. http://www.gov.ns.ca webcite (accessed 9 February 2011)
• [11]Rezaie A, Quan H, Fedorak RN, Panaccione R, Hilsden RJ: Development and validation of an administrative case definition for inflammatory bowel diseases. Can J Gastroenterol 2012, 26(10):711-17.
• [12]AS Institute Incorporation: SAS Institute Incorporation. NC, USA: SAS Institute Incorporation, Cary; 2002–2003
• [13]Fransoo R, Martens P, Burland E, Prior H, Burchill C, Chateau D, Walld R, The Need to Know Team: Sex Differences in Health Status, Health Care Use, and Quality of Care: A Population-Based Analysis for Manitoba's Regional Health Authorities. Manitoba Centre for Health Policy: Winnipeg, MB; 2005.
• [14]Kappelman MD, Moore KR, Allen JK: Recent Trends in the Prevalence of Crohn's Disease and Ulcerative Colitis in a Commercially Insured US Population. Dig Dis Sci 2013, 58(2):519-25.
• [15]Ekbom A, Helmick C, Zack M, Adami HO: The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991, 100(2):350-8.
• [16]Green C, Elliott L, Beaudoin C, Bernstein CN: A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol 2006, 164(7):615-23.
• [17]Sedlack RE, Nobrega FT, Kurland LT, Sauer WG: Inflammatory colon disease in Rochester, Minnesota, 1935–1964. Gastroenterology 1972, 62(5):935-41.
• [18]Romberg-Camps MJ, de Kruijs MA H-v, Schouten LJ, Dagnelie PC, Limonard CB, Kester AD, Bos LP, Goedhard J, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW: Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991–2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis 2009, 3(2):115-24.
• [19]Chouraki V, Savoye G, Dauchet L, Vernier-Massouille G, Dupas JL, Merle V, Laberenne JE, Salomez JL, Lerebours E, Turck D, Cortot A, Gower-Rousseau C, Colombel JF: The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988–2007). Aliment Pharmacol Ther 2011, 33(10):1133-42.
• [20]Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM: Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011, 17(1):423-39.
• [21]Prenzel F, Uhlig HH: Frequency of indeterminate colitis in children and adults with IBD - a metaanalysis. J Crohns Colitis 2009, 3(4):277-81.
• [22]García Rodríguez LA, González-Pérez A, Johansson S, Wallander MA: Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005, 22(4):309-15.
• [23]De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, Fernandez B, Lee NS, Niyonsenga T: Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007, 357(2):135-42.